Iluvien (Fluocinolone Acetonide Intravitreal Implant; Alimera Sciences) for treatment of diabetic macular edema
HAYES, Inc.
Record ID 32016000957
English
Authors' recommendations:
Description of Technology: Iluvien (fluocinolone acetonide intravitreal implant; Alimera Sciences) is a sterile, nonbiodegradable, intravitreal implant in a polyimide tube that is injected into the eye through a 25-gauge needle. The implant is 3.5 millimeters (mm) in length and 0.37 mm in diameter, and contains 0.19 milligrams of fluocinolone acetonide (FA), a potent glucocorticoid receptor agonist. The FA is released at an initial rate of 0.25 micrograms per day. It is intended for use for up to 3 years. FA is not detected in plasma of humans implanted with Iluvien.
Patient Population: Iluvien is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=44526
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Intravitreal Injections
- Diabetic Retinopathy
- Fluocinolone Acetonide
- Macular Edema
- Drug Implants
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.